EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	213038	ANDA	Laurus Labs Limited	42385-929-18	180 TABLET, FILM COATED in 1 BOTTLE (42385-929-18)	2020-05-14
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	213038	ANDA	Laurus Labs Limited	42385-929-30	30 TABLET, FILM COATED in 1 BOTTLE (42385-929-30)	2020-05-14
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	213038	ANDA	Laurus Labs Limited	42385-929-31	30 TABLET, FILM COATED in 1 BOTTLE (42385-929-31)	2020-05-14
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 30, 2025

Introduction

The antiretroviral combination of Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate (TDF) remains a cornerstone in the global fight against HIV/AIDS. These compounds, collectively administered in fixed-dose formulations, offer effective viral suppression and improve patient adherence. Supply chain integrity for these drugs is critical, encompassing a range of global and regional suppliers spanning manufacturing, distribution, and licensing agreements. This report details the primary suppliers for each component, explores manufacturing and supply chain dynamics, and assesses future supply considerations.

Overview of the Components

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), widely used in first-line HIV treatment.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), offering broad antiviral activity.
Tenofovir Disoproxil Fumarate (TDF) is a nucleotide reverse transcriptase inhibitor (NtRTI), integral in antiretroviral regimens.

The fixed-dose combination enhances adherence, reduces pill burden, and streamlines procurement processes.

Major Suppliers and Manufacturers

Efavirenz Suppliers

Efavirenz’s manufacturing landscape has largely centered around generic pharmaceutical companies due to patent expirations and global demand:

Macleods Pharmaceuticals (India): A leading producer of Efavirenz, already supplying large volumes for global health programs.
Hetero Labs (India): Major manufacturer for both domestic and international markets, including supply to the Global Fund and PEPFAR.
Intas Pharmaceuticals (India): Active participant in supplying Efavirenz generics for global markets.
Aurobindo Pharma (India): Significant producer, with products approved by regulatory authorities worldwide.
Lupin Pharmaceuticals (India): Offers Efavirenz formulations for a broad customer base.

These companies primarily supply generic versions, aligned with WHO prequalification standards.

Lamivudine Suppliers

Lamivudine’s market is dominated by a handful of large pharmaceutical firms with extensive manufacturing capacity:

Biochem Pharmaceutical Industries (Egypt): One of the earliest regional manufacturers, now producing generic Lamivudine for international markets.
Mylan (now part of Viatris): Historically a significant supplier with a broad portfolio of antiretrovirals.
Hetero Labs (India): As noted, a prominent producer of multiple ARV drugs including Lamivudine.
Cipla (India): Noted for producing affordable Lamivudine formulations, supporting global HIV programs.
Aurobindo Pharma (India): Regular supplier of generic Lamivudine.

Tenofovir Disoproxil Fumarate Suppliers

TDF’s complex synthesis and high demand have led to concentration among major pharmaceutical manufacturers:

Gilead Sciences (United States): Original developer and primary patent holder until patent expiration; now supplies TDF through licensing agreements to generic manufacturers in developing countries.
Mylan/Viatris: Licensed to produce TDF in multiple countries, enabling a broad supply base.
Hetero Labs (India): A key licensed producer of TDF, supplying to global markets.
Aurobindo Pharma (India): Offers high-quality TDF, with WHO prequalification and regulatory approvals.
Dr. Reddy’s Laboratories (India): Also licensed for generic TDF production.

Global Licensing and Patent Considerations

Gilead’s patent estate ended in many low- and middle-income countries around 2020, facilitating generic production. Licensing agreements, notably through the Medicines Patent Pool (MPP), have further expanded supply options by granting licenses to multiple manufacturers, increasing competition and reducing costs.

Gilead’s Licensing

Licenses include Mylan, Aurobindo, Hetero, and others, allowing them to produce TDF and related compounds for global markets.
These licenses accelerate manufacturing capacity and enable price reductions, especially in resource-limited settings.

Manufacturing and Supply Chain Challenges

Raw Material Availability: The synthesis of these drugs demands high-purity intermediates. Disruptions in raw material supply chains can impact production capacities.
Regulatory Approvals: Variability in approvals across jurisdictions influences the geographical availability of these drugs.
Manufacturing Capacity Constraints: Despite the number of licensed manufacturers, capacity bottlenecks can arise during global surges in demand, especially during pandemics or health crises.
Quality Assurance: Ensuring Good Manufacturing Practice (GMP) compliance remains essential to prevent substandard formulations entering the supply chain.

Market Dynamics and Future Outlook

The impending expiration of patents and the success of licensing agreements continue to shape the supplier landscape. The proliferation of generic manufacturing has driven costs downward, expanding access. However, concerns persist regarding supply security, especially in the context of geopolitical tensions, raw material shortages, and regulatory uncertainties.

Innovations, such as the development of tenofovir alafenamide (TAF), are gradually replacing TDF due to better safety profiles, potentially shifting the supply chain's focus towards newer formulations. Nevertheless, TDF-based medications remain vital in current treatment protocols, sustaining demand for existing suppliers.

Regional Supply Considerations

Africa and Southeast Asia: Rely heavily on Indian manufacturers due to cost advantages, with WHO prequalified suppliers such as Aurobindo, Hetero, and Cipla.
Latin America and Europe: Sourcing includes both licensed generics and branded products from multinational pharmaceutical companies.
United States and other high-income countries: Often rely on original formulations or proprietary products from Gilead or authorized generic producers.

The distribution network's robustness lays a foundation for predictable supply, but regional disparities necessitate strategic stockpiling and diversified sourcing to prevent shortages.

Regulatory and Policy Impact

The equitable distribution of ARVs depends heavily on international policies and procurement guidelines. WHO prequalification standards facilitate supplier access to global procurement channels, ensuring quality and safety. Supply chain resilience increasingly hinges on flexible licensing, strategic stockpiling, and capacity expansion initiatives.

Key Takeaways

Indian API Manufacturers Dominate Supply: Companies like Hetero, Aurobindo, Cipla, and Mylan are primary suppliers for Efavirenz, Lamivudine, and TDF, benefitting from cost efficiencies and licensing agreements.
Licensing Accelerates Production: Gilead’s licensing through MPP and other arrangements democratize access, expanding the supplier base and lowering costs.
Manufacturing Capacity and Raw Materials Are Vital: Ensuring raw material availability and high GMP standards is crucial to prevent shortages.
Emerging Treatment Options Will Shift Demand: Adoption of newer agents like TAF may influence future supply needs and supplier strategies.
Regional Dependencies Must Be Managed: Diversified sourcing and regional manufacturing capabilities underpin supply resilience in resource-limited settings.

FAQs

1. Who are the top global suppliers for Efavirenz?
Primarily Indian generic manufacturers such as Macleods, Hetero, Intas, and Aurobindo dominate the supply, supported by licensing agreements and WHO prequalification.

2. How has patent expiration affected the supply of Tenofovir Disoproxil Fumarate?
Patent expirations and licensing via the Medicines Patent Pool have enabled numerous generic manufacturers, notably Aurobindo and Hetero, to produce affordable TDF for global markets.

3. Are there risks associated with dependency on a few key suppliers?
Yes. Concentration among a limited number of producers can pose risks related to supply disruptions, raw material shortages, or regulatory hurdles.

4. What role does licensing play in expanding the supply chain?
Licensing agreements, especially those managed through the MPP, allow multiple manufacturers to produce TDF and other ARVs, increasing capacity and reducing costs.

5. Will newer ARV drugs impact the supply chain for Efavirenz, Lamivudine, and TDF?
Yes. The introduction of drugs like TAF and integrase inhibitors may gradually shift demand, but Efavirenz, Lamivudine, and TDF remain essential in many treatment regimens globally.

References

[1] World Health Organization. WHO Prequalification of Medicines Programme. Available at: WHO PQ

[2] Medicines Patent Pool. Licensing Agreements. Available at: MPP Licensing

[3] Gilead Sciences. TDF Licensing and Patent Information. Available at: Gilead

[4] Global Fund. Procurement Guideline for ARVs. Available at: Global Fund Procurement

[5] UNICEF Supply Division. Access to Essential Medicines. Available at: UNICEF Supply

Suppliers and packagers for EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE